



## Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference

March 10, 2022

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class<sup>1</sup> therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17, 2022 at 10:40 a.m. ET.

To access the live or archived recording of the company presentation, please visit the investor section of the Tempest website at <https://ir.tempesttx.com>.

### About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPAR $\alpha$  and EP2/EP4, respectively. Both TPST-1120 and TPST-1495 are advancing through Phase 1 clinical trials designed to study both agents as monotherapies and in combination with other approved agents. In collaboration with F. Hoffmann La Roche, TPST-1120 is also advancing through a randomized first line, global, Phase 1b/2 clinical study in combination with the standard-of-care regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company's website at [www.tempesttx.com](http://www.tempesttx.com).

### Investor Contact:

Sylvia Wheeler  
Wheelhouse Life Science Advisors  
[swheeler@wheelhousesa.com](mailto:swheeler@wheelhousesa.com)

### Media Contact:

Aljanae Reynolds  
Wheelhouse Life Science Advisors  
[areynolds@tempesttx.com](mailto:areynolds@tempesttx.com)

<sup>1</sup> If approved